218431-08-4

Basic information

• Product Name: 8-BroMo-6-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine
• Synonyms: 8-BroMo-6-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine;9H-Purine, 8-broMo-6-chloro-9-(tetrahydro-2H-pyran-2-yl)-;8-bromo-6-chloro-9-(oxan-2-yl)-9H-purine;8-Bromo-6-chloro-9-(tetrahydro-pyran-2-yl)-9H-purine
• CAS NO: 218431-08-4
• Molecular Formula: C₁₀H₁₀BrClN₄O
• Molecular Weight: 317.5696
• Mol File: 218431-08-4.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 8-BroMo-6-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine(CAS DataBase Reference)
• NIST Chemistry Reference: 8-BroMo-6-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine(218431-08-4)
• EPA Substance Registry System: 8-BroMo-6-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine(218431-08-4)

Safety Data

• Hazardous Substances Data: 218431-08-4(Hazardous Substances Data)

Usage

General Description

8-Bromo-6-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine is a synthetic chemical compound with the molecular formula C11H11BrClN4O, which belongs to the purine class of compounds. It is a derivative of purine, which is a heterocyclic aromatic organic compound. This chemical is commonly used in pharmaceutical research and drug development, particularly in the field of antiviral and antineoplastic agents. Its unique structure and properties make it a potential candidate for the design and synthesis of new bioactive compounds. The presence of bromine, chlorine, and tetrahydro-2H-pyran-2-yl functional groups in its structure gives it valuable pharmacological properties and potential applications in the treatment of various diseases.

Upstream product

• 7306-68-5 6-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine 

Relevant articles and documents

Design, Synthesis, and Activity Evaluation of Novel Acyclic Nucleosides as Potential Anticancer Agents in Vitro and in Vivo

In the present work, 103 novel acyclic nucleosides were designed, synthesized, and evaluated for their anticancer activities in vitro and in vivo. The structure-activity relationship (SAR) studies revealed that most target compounds inhibited the growth of colon cancer cells in vitro, of which 3-(6-chloro-9H-purin-9-yl)dodecan-1-ol (9b) exhibited the most potent effect against the HCT-116 and SW480 cells with IC50 values of 0.89 and 1.15 μM, respectively. Furthermore, all of the (R)-configured acyclic nucleoside derivatives displayed more potent anticancer activity compared to their (S)-counterparts. Mechanistic studies revealed that compound 9b triggered apoptosis in the cancer cell lines via depolarization of the mitochondrial membrane and effectively inhibited colony formation. Importantly, compound 9b inhibited the growth of the SW480 xenograft in a mouse model with low systemic toxicity. These results indicated that acyclic nucleoside compounds are viable as potent and effective anticancer agents, and compound 9b may serve as a promising lead compound that merits further attention in future anticancer drug discovery.